CAPTIVATE: ibrutinib/venetoclax delivers high rates of uMRD in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:04 5 years ago 436 Далее Скачать
Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma OncLive 1:56 7 years ago 266 Далее Скачать
Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCL OncLive 1:08 7 years ago 252 Далее Скачать
Dr. Tam Discusses the Side Effect Profile of Duvelisib in CLL OncLive 0:52 6 years ago 230 Далее Скачать
CAPTIVATE: 1-year DFS results from the MRD cohort in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:17 4 years ago 106 Далее Скачать
CAPTIVATE: Ibrutinib and venetoclax in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:21 2 years ago 371 Далее Скачать
Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:14 6 years ago 108 Далее Скачать
Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL OncLive 1:08 7 years ago 206 Далее Скачать
CAPTIVATE and beyond: combination therapies for CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:40 6 years ago 66 Далее Скачать
CAPTIVATE study: outcomes in patients with uMRD following cessation of ibrutinib plus venetoclax VJHemOnc – Video Journal of Hematology & HemOnc 1:34 1 year ago 107 Далее Скачать
Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19 OBRoncology 0:45 5 years ago 31 Далее Скачать
CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ecancer 11:23 3 years ago 92 Далее Скачать
